SEVENE USA – Trademark Portfolio
Entity Type: 03
SEVENE USA holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 5 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 4 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include OLLOPETS and HOMEOPATHY FOR ALL. The owner is based in Los Angeles, CA.
15335 Morrison Street, Suite 300
Los Angeles, CA 91403
Showing of trademarks Trademarks
Trademark Classifications
SEVENE USA's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Paper and cardboard; printed matter; bookbinding material; photographs; stationery
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does SEVENE USA have?
SEVENE USA has 5 U.S. trademarks filed with the USPTO. Of these, 2 registered, 3 cancelled.
What trademark classes does SEVENE USA file in?
SEVENE USA files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 44 (Medical Services), Class 16 (Paper Goods), Class 35 (Advertising & Business). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are SEVENE USA's most well-known trademarks?
SEVENE USA's registered trademark portfolio includes well-known marks such as OLLOPETS and HOMEOPATHY FOR ALL. These are among 2 currently registered trademarks in the portfolio.
What is SEVENE USA's trademark registration success rate?
SEVENE USA has a 40% trademark registration rate, with 2 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.